ATTENTION NYSE: NVO INVESTORS: Contact Berger Montague About a Novo Nordisk A/S Class Action Lawsuit

Core Viewpoint - Berger Montague PC is investigating claims against Novo Nordisk A/S following a class action lawsuit related to the company's lowered sales and profit guidance for the second half of fiscal 2025 [1][3]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk lowered its sales and profit guidance for the second half of fiscal 2025, attributing this to persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for its products Wegovy® and Ozempic® [3]. - Following the announcement, Novo's stock price fell from $69.00 to $53.94 per share, marking a one-day decline of over 21% [3]. Group 2: Legal Actions - A class action lawsuit has been filed against Novo Nordisk, and investors who purchased or acquired Novo securities between May 7, 2025, and July 28, 2025, may seek to be appointed as lead plaintiff representatives by September 30, 2025 [2].